产品
编 号：F107505
分子式：C18H20Cl2N6O2
分子量：423.3
分子式：C18H20Cl2N6O2
分子量：423.3
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1275582-97-2
产品详情
生物活性：
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI).
体内研究：
Ibezapolstat is poorly absorbed and apparently nontoxic in the hamster C. difficile-associated disease (CDAD) model (potential for achieving a high local concentration at the site of C. difficile infection in the colon).Ibezapolstat (50 mg/kg; p.o.; twice daily; for 3 days) shows strong anti-C. difficile properties in the hamster CDAD model.Animal Model:Female golden Syrian hamsters (80-90 g), CDAD model
Dosage:50 mg/kg
Administration:Oral administration, twice daily, for 3 days
Result:Completely protected C. difficile-infected animals for a period of up to 5 days.
体外研究：
Ibezapolstat binds to and inhibits DNA pol IIIC from aerobic and low G+C Gram-positive bacteria.Ibezapolstat displays antibacterial activities against broad spectrum ofC. difficilepathogens, with an MIC range of 1-8 μg/mL for a panel of 104 clinical isolates ofC. difficile overall in vitro.
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI).
体内研究：
Ibezapolstat is poorly absorbed and apparently nontoxic in the hamster C. difficile-associated disease (CDAD) model (potential for achieving a high local concentration at the site of C. difficile infection in the colon).Ibezapolstat (50 mg/kg; p.o.; twice daily; for 3 days) shows strong anti-C. difficile properties in the hamster CDAD model.Animal Model:Female golden Syrian hamsters (80-90 g), CDAD model
Dosage:50 mg/kg
Administration:Oral administration, twice daily, for 3 days
Result:Completely protected C. difficile-infected animals for a period of up to 5 days.
体外研究：
Ibezapolstat binds to and inhibits DNA pol IIIC from aerobic and low G+C Gram-positive bacteria.Ibezapolstat displays antibacterial activities against broad spectrum ofC. difficilepathogens, with an MIC range of 1-8 μg/mL for a panel of 104 clinical isolates ofC. difficile overall in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备